Wissenschaftliche Arbeiten

Uzm. Dr. Abdussamet Çelebi

63 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

    Supportive Care in Cancer, 2023

    DOI 10.1007/s00520-023-07791-7 PMID 37162602 4 Zitationen (Europe PMC) Quelle: ORCID

  2. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib

    Journal of Oncological Science, 2023

    DOI 10.37047/jos.2022-94250 Frei zugänglicher VolltextQuelle: ORCID

  3. 230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101418 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters

    Acta Radiologica, 2023

    DOI 10.1177/02841851221140504 PMID 36447438 2 Zitationen (Europe PMC) Quelle: ORCID

  5. L’indice de comorbidité de Charlson ajusté selon l’âge est un outil pronostique précieux dans le sarcome des tissus mous opérable du tronc et des extrémités

    Revue de Chirurgie Orthopédique et Traumatologique, 2023

    DOI 10.1016/j.rcot.2022.11.016 Quelle: OpenAlex

  6. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy

    Cureus, 2023

    DOI 10.7759/cureus.40548 PMID 37465788 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  7. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

    The Breast, 2023

    DOI 10.1016/j.breast.2023.06.006 PMID 37343321 22 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  8. Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically

    Oncology, 2023

    DOI 10.1159/000531722 PMID 37379817 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  9. 468P Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.644 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma

    Nutrition and Cancer, 2022

    DOI 10.1080/01635581.2022.2063349 PMID 35416100 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  11. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

    Breast, 2022

    DOI 10.1016/j.breast.2022.09.009 PMID 36208540 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  12. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities

    Orthopaedics & Traumatology Surgery & Research, 2022

    DOI 10.1016/j.otsr.2022.103491 PMID 36455864 6 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  13. Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2021-84514 Frei zugänglicher VolltextQuelle: OpenAlex